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Cyclophosphamide (cy) is an alkylating agent used to treat malignancies and immune-mediated inﬂammatory nonmalignant
processes. It has been used as a treatment in cases of worsening multiple sclerosis (MS). Cy is currently used for patients whose
disease is not controlled by beta-interferon or glatiramer acetate as well as those with rapidly worsening MS. The most commonly
used regimens involve outpatient IV pulse therapy given with or without corticosteroids every 4 to 8 weeks. Side eﬀects include
nausea,headache,alopecia,pain,maleandwomeninfertility,bladdertoxicity,andriskofmalignancy.Previousstudiessuggestthat
cy is eﬀective in patients in the earlier stages of disease, where inﬂammation predominates over degenerative processes. Given that
early inﬂammatory events appear to correlate with later disability, a major question is whether strong anti-inﬂammatory drugs,
such as cy, will have an impact on later degenerative changes if given early in the disease to halt inﬂammation.
1.Introduction
Multiple sclerosis (MS) is an acquired inﬂammatory
immune-mediated disorder of the central nervous system,
characterized by inﬂammation, demyelination, and primary
or secondary axonal degeneration. It clinically manifests
with signs of multiple neurological dysfunctions, followed
by recovery or increasing disability. Cyclophosphamide (cy)
(the generic name for Endoxan, Cytoxan, Neosar, Procytox,
and Revimmune), also known as cytophosphane, is a
nitrogen mustard alkylating agent from the oxazophorine
group (Figure 1). An alkylating agent adds an alkyl group
(CnH2n+1) to DNA. It attaches the alkyl group to the guanine
base of DNA, at number 7 nitrogen atom of the imidazole
ring. This leads to the synthesis of aberrant couples of
cytosin-tymine. The DNA reparation system of the cells
removes the modiﬁed guanine, triggering cell apoptosis.
Cy is converted by mixed function oxidase enzymes in the
liver to active metabolites. The main active metabolite is
4-hydroxycyclophosphamide, which exists in equilibrium
with its tautomer, aldophosphamide. Most of the aldophos-
phamide is oxidised by the enzyme aldehyde dehydrogenase
(ALDH) to make carboxyphosphamide. The intracellular
level of this enzyme has been shown to be directly related
to cellular resistance to activated cy and is believed to be
important in the survival of cells capable of repopulating
marrow in autologous bone marrow transplant procedures
[1]. Both hematopoietic progenitors and intestinal crypt
stem cells display high levels of cytosolic ALDH and are
accordingly relatively resistant to cy. Tumor cell resistance
to cy may also result from high cytosolic ALDH levels [2].
A small proportion of aldophosphamide is converted into
phosphoramide mustard and acrolein. Acrolein is toxic to
the bladder epithelium and can lead to hemorrhagic cystitis
[3].
Cy and the related nitrogen mustard-derived alkylating
agentifosfamideweredevelopedbyNorbertBrockandASTA
(now Baxter Oncology). Brock and his team synthesised
and screened more than 1,000 candidate oxazaphosphorine
compounds. They converted the base nitrogen mustard into
a nontoxic “transport form”. This transport form was a
prodrug, subsequently actively transported into the cancer
cells. Once in the cells, the prodrug was enzymatically
converted into the active, toxic form.2 Autoimmune Diseases
Cy is widely used, together with other antineoplastic
drugs, for the treatment of leukemias, lymphomas, and
carcinomas but also for the treatment of immune mediated
diseases such as vasculitis (Wegener’s granulomatosis, pol-
yarteritis nodosa) [4, 5], kidney diseases (lupus nephritis
idiopathic nephrotic syndrome) [6], and for the treatment
of severe systemic-onset juvenile rheumatoid arthritis [7]
and interstitial lung disease associated with collagen vascular
diseases [8]. Cy is also used for neurological diseases
such as refractory cases of polymyositis or inﬂammatory
neuropathies [9, 10].
Cy was ﬁrst tested in MS in 1966 [11]. Even if it is not
a drug licensed for MS, due to the lack of adequate phase
III studies, cy has been used for the treatment of selected
MS patients who have had a partial response to previous
treatment with the FDA-approved drugs. Furthermore, we
thinkthatcycouldhavebeenpartiallyignoredbyresearchers
and pharmaceutical companies due to the low cost of
the drug. This could partly explain the lack of adequate
randomized controlled studies.
This paper will focus on the results obtained with cy to
treat MS patients. In addition, it will report the diﬀerent
protocols of cy use, highlighting results and side eﬀects.
2.Immunologic Effects
In the experimental autoimmune encephalomyelitis (EAE)
mouse system, two distinct T cell subsets have been deﬁned.
Th1 cells secrete IL-2 and IFN-γ and mediate delayed-type
hypersensitivity, whereas Th2 cells secrete predominantly IL-
4, IL-5, and IL-10 and mediate humoral immunity [12, 13].
Cells that secrete predominantly TGF-β have been termed
T h 3o rT - r e gc e l l s[ 14, 15], while cells that secrete IL-17, IL-
21, and IL-22 have been termed Th17. In the EAE mouse
model, T cells producing Th1 cytokines can transfer disease
[16, 17], while spontaneous recovery from EAE correlates
with a switch to TGF-β and Th2 cytokines [18–20].
MS is considered to be mediated by T helper type-1
(Th1) cells [21–23]. In humans, increased production of
interferon-γ (IFN-γ) by peripheral blood mononuclear cells
(PBMCs) has been shown to precede clinical attacks [24],
and injection of recombinant IFN-γ induces exacerbations
of the disease in patients with MS [25]. Cy acts on cell-
mediated and humoral immunity through its eﬀects on both
T and B cells. It has been shown to enter the nervous
system, as it can be recovered from the cerebrospinal ﬂuid
of treated multiple sclerosis patients [26, 27]. Among the
FDA-approved drugs, currently used in MS, only ﬁngolimod
crosses the blood brain barrier and may, therefore, have
direct eﬀects on the CNS [28]; the relationship between
cladribine(experimentaldrug)andthebloodbrainbarrieris
unclear, the concentration of cladribine in the cerebrospinal
ﬂuid is around 25% of what is available at the plasma level
in patients without CNS disease [29]. Earlier studies in MS
patients treated with cy had demonstrated a lymphopenia
induced by cy involving both T and B cells [30, 31]w i t ha
more pronounced eﬀect on CD4 cells [32, 33]. More recent
studies showed that cy could also have selective eﬀects on
the immune system. Speciﬁcally, it increases Th2 cytokine
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such as IL-4, IL-5, IL-10, and TGF-β, a cytokine secreted
by regulatory T cells (T-reg), and for this reason, cy is
associated with eosinophilia [34]. Patients treated with cy
showed an increased frequency of both MBP and PLP cells
secreting IL-4 [35], while this eﬀect was not observed in
tetanus-toxoid-secretingcellsandinMSpatientstreatedwith
methylprednisolone [36].
ThepreferentialshifttowardsaTh2-typepatternwasalso
seen in terms of chemokine receptor expression. Chemokine
receptors have been found to diﬀerentiate between polarized
T helper type-1 (Th1) and type-2 (Th2) lymphocytes.
The chemokine receptors CCR5 and CXCR3 are expressed
primarily on Th1 cells and CCR3, CCR4, and CCR8 on
Th2 cells. Previous studies of the expression of chemokine
receptorsinMSshowedthatactiveMSplaquesareinﬁltrated
by CCR5+ and CXCR3+ T cells that are major producers
of IFN-γ. In MS patients, cy induced a marked increase in
the percentage of CCR4+ T cells that produced high levels of
IL-4 and reversed the increase in the percentages of IFN-γ-
producing CCR5+ and CXCR3+ CD8+ T cells [37].
IL-12 is a heterodimeric cytokine produced mostly by
phagocytic cells and induces cytokine production, primarily
IFN-γ, from T cells. Several studies in humans [38, 39]a n d
in mice [40, 41] have assigned a role to IL-12 (linked to
IL-23 and IL-17) as the promoter of Th1 cell generation,
acting in antagonism with IL-4, the major promoter of Th2
responses. Administration of IL-12 to mice after the transfer
of encephalitogenic cells resulted in increased severity and
duration of EAE; treatment with anti-IL-12 antibodies
substantiallyreducedtheincidenceandseverityofadoptively
transferredEAE[42].ElevatedserumlevelsofIL-12aswellas
an increase in T cell receptor-mediated IL-12 secretion have
beenreportedinthechronicprogressiveformofMS[43,44].
The results of these studies suggest that IL-12 could play an
important role in the pathogenesis of EAE and MS.
In patients treated with methotrexate, methylpred-
nisolone, or cy/methylprednisolone, only the last treatment
normalized the elevated IL-12 production. Patients followed
prospectively before and after starting CY/MP treatment,
in fact, showed a gradual decrease in IL-12 and IFN-γ
production and an increase in IL-4 and IL-5 [45, 46].
In summary, probably a Th1-type cytokine bias has a
role in the pathogenesis of the disease and is reversed by
cy/MP treatment with an associated Th2 and TGF-β (Th3-
Treg) type response.Autoimmune Diseases 3
3.ClinicalData
Several reports have been published on the clinical eﬀects of
cy in MS. Many reports showed that cy is eﬀective in MS,
but not all studies have shown positive eﬀects. La Mantia et
al. in 2007 conducted an evaluation of the published studies
performed on cy in MS. Of the 326 identiﬁed references,
80 were selected for full review and only four RCTs were
selected for the ﬁnal analysis. The authors concluded that
intensive immunosuppression with cy (alone or associated
with ACTH or steroids) in patients with progressive MS
compared to placebo or no treatment (152 participants)
did not prevent the long-term (12–18–24 months) risk of
evolution to a next step of the EDSS. However, the authors
suggested that the lack of eﬃcacy in progressive MS does
not lead to the conclusion that the drug is not eﬀective in
the inﬂammatory phase of the disease [47]. Cy, in fact, is
considered a treatment option in several recently published
MStreatmentguidelines[48]. However, a major question for
physicianstreatingpatientswithMSishowcyshouldbeused
to obtain the best results and to avoid side eﬀects. As we will
see in the following paragraphs, the studies conducted since
1966 in MS patients give us some answers.
4.EarlyStudies
The ﬁrst clinical trial with cy was published at the end of the
1950s [49].
In 1966, Aimard et al. described the arrest of the disease
observed in a progressive case of MS using cy [11]. In
subsequent years, the eﬀects of the drug on patients with a
progressive form of the disease (Table 1)w e r ed e s c r i b e d[ 50–
55]. In 1975, Drachman et al. observed no eﬀects using 4–
5mg/kg of cy given for 10 successive days for the treatment
of acute attacks (see Table 1)[ 56]. In 1977, Gonsette et al.
described, in an open-label, uncontrolled study, the results
obtained with cy in 201 relapsing/remitting patients [57]
(Table 1). It is interesting to note that more positive eﬀects
were observed in those patients with the shortest length of
disease; on the contrary, more severely disabled patients did
not beneﬁt from cy treatment. In 1983, the ﬁrst clinical trial
with a rigorous design (randomized and controlledtrial) was
performedtoevaluatetheclinicaleﬀectsofcyinMSpatients.
Hauser et al. [58] evaluated patients with progressive MS
treated with a 2- to 3-week course of cy, intravenously 400–
500mg/day, to achieve leukopenia of 2000/mm3 plus ACTH
compared to a similar group treated with ACTH alone and
to a group that received plasma exchange, ACTH, and oral
cy. The results showed that 80% (16/20) of the cy-treated
patients had improved or were stable at 1 year compared to
only 20% (4/20) in the ACTH-treated group. The plasma
exchange group showed an intermediate (50%) response.
Positive clinical results were observed on disability with a
very low number of treatment failures. Moreover, analysis of
the patient proﬁles demonstrated that the patients who were
relatively young (35 years) and with a short disease duration
(between 2 and 3 years) were the best clinical responders. It
was also reported that 11/20 (55%) patients who were stable
or who had improved at the 1-year follow-up experienced
reprogressionoftheirdiseaseinthe secondorthirdyearafter
treatment suggesting that a short period of treatment was
not suﬃcient. In 1993, the Northeast Cooperative Treatment
Group demonstrated that patients between 18 to 40 years
old receiving cy boosters every other month for 2 years, did
not show a reprogression of the disease and that there were
no diﬀerences between the modiﬁed induction regimen and
the previous published regimen to prevent or delay disease
reprogression [59]. This study led the way for currently used
protocols in which treatment is given as outpatient pulses
similar to lupus nephritis treatment.
The Northeast Cooperative Study results were challenged
by the results obtained with cy, on patients with progressive
MS,fromtheCanadianCooperativeMultipleSclerosisgroup
study [60] and by the Kaiser study [61].
The ﬁrst trial, a single blinded randomized and placebo-
controlled multicentre study, included 168 progressive MS
patients.Theinvestigatorsdidnotﬁndsigniﬁcantdiﬀerences
intime-to-treatmentfailure,comparingpatientstreatedwith
intravenous cy and oral prednisone, patients treated with
oral cy and oral prednisone on alternate days plus weekly
plasma exchange and one further group of patients treated
with oral placebo and sham plasma exchange. In the Kaiser
study, 22 progressive MS patients received 400–500mg of
cy, IV, 5 days per week, until the leukocyte count fell below
4000/mm3, and were compared to 20 patients receiving folic
acid in a randomized, single-blind study. The similar disease
progression in the two groups provided evidence of a lack of
substantial beneﬁts of cy treatment.
The potential reasons for diﬀerences between these
two studies and the 1983 NEJM study and the Northeast
Cooperative Treatment Group study have been extensively
debated in the literature [62–64].
In summary, the studies cited seem to delineate a role
for cy in the treatment of patients with an inﬂammatory
component of the disease (early, aggressive, and inﬂamma-
tory MS). There is evidence of poor or no beneﬁt when cy is
administered in both primary and secondary progressive MS
patients.
5. Recent Studies
Inrecentyears,consideringpreviousstudies,mostphysicians
have used cy to treat RR-MS, SP-MS, or rapidly deteriorating
MS patients with intermittent intravenous (monthly or
bimonthly) pulse therapy, alone or in combination with
DMTs, and, less frequently, they have used an induction
protocol (see Table 2). Of the several published studies
(see Table 1), three must be highlighted because they were
performed on patients with aggressive forms of the disease.
Weinstock-Guttman et al. described the eﬀects of cy (open-
label) in 17 consecutive patients with “fulminant MS”
(deﬁned as a deterioration of more than one and a half
points on the EDSS for more than 3 months); after 24
months, 69% of patients were stable or had improved [65].
Gobbini et al. reported clinical stability in ﬁve patients
with rapidly deteriorating relapsing-remitting MS who were
treated monthly with cy for 6 months and then on alternate4 Autoimmune Diseases
Table 1: Clinical studies of cy in the treatment of MS.
Date Author No. of
patients Type of MS Regimen Comments and side eﬀects
Study of cy in to treat the relapse of MS
1975 Drachman et al. 6 Acute attacks 4–5mg/kg IV for 10 successive days No eﬀect observed on recovery from
relapse
Studies of cy in progressive MS
1966 Aimard et al. 1 Progressive Arrest of disease in progressive MS
patients,
1967 Girard et al. 30 Progressive 200mg/day IV for 4–6 weeks; (4–9g
total) 50% improved or stable at 2 years
1969 Millac and Miller 16 Progressive Oral, 75–100mg/day Toxicity associated with low white
blood counts
1975 Hommes et al. 32 Progressive 100mg qid + 50mg prednisone bid
(8g total over 20 days)
Stabilization in 69% of patients.
Better results were found in patients
with shorter duration of their disease
1980 Hommes et al. 39 Progressive 400mg cy + 100mg prednisone. 8g
total
Stabilization in 69% of patients.
Open label, uncontrolled
1981 Theys et al. 21 Progressive 6–8g given over 3–4 weeks No eﬀect in patients with moderately
advanced MS over 2 years
1983 Hauser et al. 20 Progressive 400–500mg/day IV for 10–14 days +
ACTH
16/20 stabilized at 1 year versus 4/20
w i t hA C T Ha n d9o u to f1 8w i t h
plasma exchange regimen
1987 Goodkin et al. 27 Progressive
Inpatient induction for 10–14 days
with IV cy/ACTH or outpatient
induction with 700mg/m2 weekly
for 6 weeks plus prednisone
Maintenance therapy of 700mg/m2
every 2 months for 24 months.
Stabilization in 59% of patients
induced at 12 months versus 17% in
nonrandomized controls
1987 Myers et al. 14 Progressive
Monthly therapy with
400–800mg/m2 oral or IV escalating
to 1200–2000mg/m2 monthly; 5–13
doses given over 5–14 months to
reduce B cell and CD4+ cells. With
and without steroids
3 improved, 9 unchanged, and 2
worsened
1987 Siracusa et al. 14 Progressive Short course of intensive cy until
WBC reached 3000
5 patients discontinued because of
side eﬀects. Patients stable, though
not improved
1988 Carter et al. 164 Progressive 2-week IV cy/ACTH regimen
81% improved or stable at 1 year.
Reprogression in 69% of patients at
mean of 17.6 months
1989 Mauch et al. 21 Progressive
8mg/kg IV at 4-day intervals until
lymphocyte count was half the initial
value. (1.9g average total dose)
20/21 patients stable at 1 year versus
7/21 patients receiving ACTH
1989 Canadian 55 Progressive 1g IV on alternate days up to 9g +
oral prednisone
No diﬀerence versus placebo
(n = 56) or plasma exchange
regimen. (n = 57)
1989 Trouillas et al. 10 Progressive IV (450mg/day) for 20 days 3 weeks
+M P
6/10 stabilized at 3 years versus 9/10
in plasma exchange regimen versus
0/10 in untreated or azathioprine
controls
1991 Likosky et al. 22 Progressive IV (400–500mg) 5 days/week until
leukocyte count fell below 4000/mm3
No diﬀerence versus placebo
(n = 21) at 12, 18, or 24 monthsAutoimmune Diseases 5
Table 1: Continued.
Date Author No. of
patients Type of MS Regimen Comments and side eﬀects
1993 Weiner et al. 256 Progressive
IV cy/ACTH induction versus
modiﬁed IV cy/ACTH induction
(600mg/m2 on days 1, 2, 4, 6, 8)
followed by 700mg/m2 IV pulses
every 2 months for 2 years
No diﬀerence between published or
modiﬁed induction (56% stable at 12
months). Beneﬁt of booster versus no
boosters at 24 and 30 months
1998 La Mantia et al. 30 Progressive
Every 2 months IV pulses
(600mg/m) for 12 months with or
without induction (300mg/m2 IV
for 9 days)
At 12 months 75% stable if induction
given; 35% stable if no induction
1999 Hohol et al. 95 Progressive
Progressive induction with 1g IV MP
for 5 days followed by IV pulse
cy/MP every 1 month for 1 year,
every 6 weeks for 1 year and every 2
months for 1 year
Response to therapy linked to
duration of disease
2003 Perini et al. 26 Progressive
IV cy/MP 800–1250mg/m2 monthly
for 1 year then every 2 months for 1
year
Clinical improvement at 2
years/reduction in Gd+ lesions and
T2 lesion volume
2004 Zephir et al. 111 Progressive IV cy/MP 700mg/m2 monthly for 1
year
Response in patients with clinical
attack in the 2 years prior to therapy
Studies of cy in relapsing-remitting and rapidly deteriorating MS
1973 Cendrowski 23 Relapsing remitting
and progressive
100–300mg IV for 16–33 days +
50mg hydrocortisone
No diﬀerence in comparison to
patients treated with ACTH or
cortisol
1977 Gonsette et al. 110 Relapsing-remitting
IV over 2 weeks to achieve
leukopenia of 2000 and lymphopenia
of 1000. (1–12 g)
Stabilization in 62% of patients over
2–4 years. Decrease in relapse rate
1980 Gonsette et al. 134 Relapsing-remitting
IV over 2 weeks to achieve
leukopenia of 2000 and lymphopenia
of 1000. (1–12 g)
Stabilization in relapse rate in 76% of
patients
1988 Killian et al. 14 Relapsing-remitting Monthly 750mg/m2 IV pulses for 1
year
A trend showing decreased relapses
in 6 treated patients versus 8 placebo
patients
1990 Milleﬁorini et al. 15 Relapsing-progressive IV cy followed by booster every 2
months for 2 years
50% clinically stable at 2 years. No
major side eﬀects
1990 D’Andrea et al. 7 Relapsing-remitting IV induction (11 doses 300mg/m2)
then every 6 months for 3 years
Decrease relapse rate in all patients at
1 year; in the following 2 years, 2
patients worsened, and others were
clinically stable
1997
Weinstock-
Guttman et
al.
17 “Fulminant”
IV 500mg/m + IV MP for 5 days
followed by maintenance therapy
with cy/methotrexate, MP or
IFN-beta-1b
13/17 (75%) patients improved or
were stable at 12 months; 9/13 (69%)
at 24 months
1999 Gobbini et al. 5 Relapsing-remitting Monthly pulses of CTX
(1000mg/m2)g i v e nf o r1 2m o n t h s
MRI outcome: decrease in Gd+
lesions following pulse CTX in all
patients treated
2000 Manova et al. 70 Relapses
I VM P( 2 0 0m g )e v e r yo t h e rd a yf o r
1 0d o s e sv e r s u sI Vc y( 2 0 0m g )o n
alternate days for 10 doses and then
monthly for 3 months (total dose:
2.6 g)
At 12 months EDSS improved in
CTX-treated group versus MP group.
No diﬀerence between groups at 1
month
2001 Khan et al. 14 Rapidly deteriorating
refractory patients
Pulse cy 1000mg/m2 given monthly
plus 20mg IV dexamethasone
Clinical improvement or stability in
14/14 patients at 6 months sustained
at 18 months following treatment6 Autoimmune Diseases
Table 1: Continued.
Date Author No. of
patients Type of MS Regimen Comments and side eﬀects
2001 Patti et al. 10
Rapidly progressive
IFN-β
nonrespondents
Monthly pulses cy 500–1500mg/m
for 18 months
Reduction in relapses, disability plus
T2 MRI burden
2002 Smith et al. 58 Rapidly deteriorating
refractory patients
3 days IV MP followed by monthly
p u l s e so fM Po rM P / c y( 8 0 0m g / m 2)
for 6 months
Less Gd+ lesions at 3 and 6 months in
CTX/MP versus MP treated subjects
2004 Patti et al. 10
Clinical and MRI
follow-up 36 months
after the
discontinuation of cy
in previous reported
patients
Monthly pulses cy 500–1500mg/m
for 18 months
Maintenance of the results obtained
in relapse rate, EDSS, T2 MRI total
lesion load and T2 lesions number
2005 Reggio et al. 30
Rapidly progressive
IFN-β
nonrespondents
500–1500mg/m2 combined with
INF-β
Reduction in relapses plus Gd+ MRI
burden
2005 de Bittencourt PR 1 Rapidly progressive IV cy/MP 3800mg accidentally given Long term remission (7 years)
2006 Gladstone 12 Deteriorating and RR
and SP MS patients 200mg per kg over 4 days
No patients increased their baseline
EDSS score more than 1.0,
improvement in quality of life after
15 months
2008 Krishman et al. 21
MS patients with
“active” MRI or
relapse or EDSS
deterioration in the
year before
50mg/kg/die for 4 consecutive days
Reduction of EDSS and of the
number of Gd+ lesions at end of
follow-up (24 months)
2009 Patti et al. 20
Active RR MS patients
(>1 relapse in the
p r i o r1 2m o n t h sa n d
>1 Gd+ MRI lesion)
Monthly cy, administered to induce a
leucopoenia below 1000×mm3,p l u s
methylprednisolone (MP) 1g for 12
months followed by IFN-β for a
further 12 months (cy group); versus
IFN-β alone for 2 years (IFN-β
group)
Reduction of relapse rate and of the
number of gadolinium-enhancing
lesions at end of follow-up (24
months). Relapse-free patients at the
second year were 80% in the cy group
versus 40% in the IFN-β group
2009 Perumal et al. 26
Active RR MS patients
(at least two relapse in
the year before)
Study of cy in pediatric MS
2009 Makhani et al. 17
Children with MS
with multiple relapses
or EDSS deterioration
in the year before
Induction therapy alone, induction
therapy with pulse maintenance
therapy or pulse maintenance
therapy alone at a dose of
600–1000mg/m2
After 1 year of treatment reduction in
relapse rate and a stabilization of
disability
months. These results were conﬁrmed by a rapid reduction
in gadolinium-enhancing lesions, seen with monthly brain
MRI scans [66]. Khan et al. reported an open-label study of
intravenous cy given monthly to 14 patients with relapsing-
remitting MS who were rapidly deteriorating (deﬁned as a
greater than three-point increase in the EDSS score in the
previous 12 months despite DMT therapy and intravenous
prednisone) [67]. Some authors have used, accidentally
or intentionally, high doses of cy. A report of a single
patient with relapsing remitting MS who, on one occasion,
accidentally received a dose of 3800mg of the drug showed
no evidence of clinical or MRI disease activity for the next 7
years [68]. An open-label study by Gladston and coworkers,
with high doses of cy (200mg per kg over 4 days), in 13
patients with treatment-refractory MS showed signiﬁcant
disease stability (no patients increased their baseline EDSS
score by more than 1.0) and improvement in quality of
life after 15 months [69]. Also, Krishman and coworkers
described the eﬀects of high doses of cy after 24 months
in 21 patients with RR-MS with “active” MRI or clinical
exacerbation in the year before or a worsening EDSS score
of 1 point or higher compared to the preceding year using an
immunoablative regimen of 50mg/kg/day for 4 consecutive
days followed by granulocyte colony stimulating factorAutoimmune Diseases 7
(GCS) 6 days aftercy. They observed a reduction of the EDSS
score and of the number of gadolinium-enhancing lesions at
the end of follow-up [70]. Makhani and coworkers reviewed
their multicentre experience with cy in the treatment of 17
children with MS. After 1 year of treatment they observed
a reduction in relapse rate and a stabilization of disability
scores [71].
6. Comparison Studies
Zipoli et al. compared the eﬃcacy and safety of intravenous
cy and mitoxantrone as second-line therapy in relapsing-
remitting or secondary-progressive MS patients. Mitox-
antrone was administered at a dosage of 8mg/m2 monthly
for 3 months, then every 3 months, until a dosage of
120mg/m2 was reached. Cy was administered at a dosage
of 700mg/m2 monthly for 12 months, then bimonthly
for a further 24 months. Seventy-ﬁve patients received
mitoxantrone (31 RR, 44 SP) and 78 cy (15 RR, 63 SP).
The two groups diﬀered only in terms of a signiﬁcantly
higher proportion of RR patients in the mitoxantrone group.
After a mean follow-up of 3.6 years, the authors observed
a lack of a signiﬁcant diﬀerence in terms of time to the
ﬁrst relapse, whereas time to disease progression was slightly
shorter in the group treated with mitoxantrone than in the
cy group. After 12 months of treatment, active MRI scans
were reduced by 69% in the mitoxantrone group and 63%
in the cy group of patients. Discontinuation due to side
eﬀects was more frequent in cy patients, but the authors
concluded that the overall tolerability of the two treatments
was acceptable [72]. Gallo et al. treated ﬁfty secondary
progressive MS patients, who had lost one or more EDSS
points in the prior two years, with cy (25 patients, mean
disease duration 13.3 years; mean EDSS score at study entry:
5.7) or mitoxantrone (25 patients, mean disease duration:
11.5 years; mean EDSS score at study entry: 5.5). SPMS
patients were treated for two years. The authors observed
a signiﬁcant reduction in both groups of relapse rate and
disability progression. Subgroups of mitoxantrone- and cy-
responding patients were characterized by a signiﬁcantly
shorter duration of the secondary progressive phase of the
disease. In these subgroups, the improvement in the EDSS
score at the end of therapy was higher than the remaining
patients. The safety proﬁles of both drugs were acceptable;
however, the authors also evaluated the cost of the two
treatments and concluded that the cy-based therapy protocol
was signiﬁcantly less expensive [73].
7. Our Experience
Our group reported on the eﬀectiveness of a combination of
cy and beta-interferon in patients with rapidly progressive
or “transitional” MS (characterized by frequent and severe
attacks plus worsening on the disability status scale). We
treated 10 such patients with monthly pulses of IV cy (500–
1500mg/m2) to obtain a lymphopenia of between 600 and
900/mm3 for 12 consecutive months and then at 2-month
intervals for a further 6 months. We found a signiﬁcant
reduction in the number of relapses, disability and T2 MRI
burden of disease with a stabilization of the disease for a
mean of 36 months after the discontinuation of cy treatment
[74, 75]. We found that the treatment was safe and well
tolerated. In the following years, we replicated this result in a
cohort of thirty rapidly deteriorating MS patients treated for
24 months with cy (500–1500mg/m2) combined with INF-β
[76].
In a randomised, multicentre trial of 59 patients with
relapsing-remitting MS, who did not respond to interferon
beta, Smith et al. observed that the combination of cy
and interferon beta-1a reduced the clinical disease activity
and gadolinium-enhancing MRI lesions in the brain [77].
In 2009, our group reported the eﬀects of cy as initial
induction therapy in “active” MS. Forty active relapsing-
remitting MS patients (>1 relapse in the prior 12 months
and >1 Gd+ MRI lesion) were randomized in two groups of
twentytoreceivemonthlycy,designedtoinducealeucopenia
below 1000×mm3, plus methylprednisolone (MP) 1g for 12
months followed by IFN-β for a further 12 months versus
IFN-β alone for 2 years. The annual relapse rate was reduced
from 1.9 observed at baseline to 0.1 in the cy group versus
0.5 in the interferon group (P = .02) at Year 2; relapse-free
patients at the second year were 80% of the cy group versus
40% of the IFN group (P = .024); and the percentage of
patients without Gd+ MRI lesions at 24 months was 90%
in the cy group versus 54% in the IFN group-2 (P = .04).
No serious adverse events were observed during follow-up.
This study supports the concept of using cy as an induction
treatment for improving the impact of IFN over time [78].
A similar approach was used by Perumal et al. They used
cy as the initial therapy in patients who had not received
DMT therapy before. All patients had experienced at least
two relapses in the year prior to therapy. Twenty-six patients
received monthly intravenous cy for 6 months followed by
initiation of immunomodulatory therapy. At year 1, the
meanEDSSscore,relapserate,andGd-enhancingperpatient
at baseline were reduced from 3.61 to 2.22, 3.42 to 0.77, and
3.55 to 0.33, respectively. These studies suggest that cy may
be used as initial therapy in relapsing-remitting MS patients
[79].
8.CyinAutologous Haematopoietic Stem-Cell
Transplantation (AHSCT) for MS
Intense immunosuppression using cy 1.5–4g/m2 total dose
over 1-2 days, to mobilize peripheral blood hematopoietic
stem cells (HSC), followed by a conditioning regimen, and
then autologous haematopoietic stem-cell transplantation
(AHSCT) has been evaluated as a possible new therapeutic
tool in severe autoimmune disorders, after it was shown to
beeﬃcaciousinanimalmodelsofimmunomediateddiseases
[80]. The conditioning regimen, the second step of the pro-
cedure, could be carried out with several protocols, the most
common protocol used is the BEAM regimen which includes
300mg/m2 carmustine at day-7, 200mg/m2 etoposide and
200mg/m2 cytarabine from day-6 to day-3, and 140mg/m2
melphalan at day-2. These drugs cross the blood-brain8 Autoimmune Diseases
Table 2: Treatment regimens.
(a) IV induction therapy: 600mg/m2 CTX given on days 1, 2, 4, 6, 8 plus MP given daily for 8 days.
(b)IVpulsetherapywithCYX/MP:CTXpulsesstartingat800mg/m2 withdoseaugmentationinordertoobtainaleukopeniaof3000/mm3
and a lynphocitopenia of 800/mm3; every 4 weeks x 18–24 months, every 2 months × 24. 1g MP given with CTX.
(c) Pulse therapy with CTX at a ﬁxed dose: CTX pulses given at 800–1000mg/m2 every 4–8 weeks for 12–24 months, given with or without
MP.
(d) Combination therapy: IV pulse CTX therapy given concomitantly with beta-interferon or glatiramer acetate in nonresponders.
barrier and possibly hit the autoreactive clones that colonize
the CNS. In North America and also in Europe, total
body irradiation (TBI) plus cy is frequently used. Another
conditioning regimen utilized in the reported studies is
BCNU 300mg/m2 plus cy 150–200mg/kg, an intermediate
intensity regimen, which eliminates etoposide and ARA-
C from the BEAM scheme. Less intense regimens, with a
prevalence of immunosuppressive and minor myeloablative
eﬀects, such as cy 200mg/kg plus alemtuzumab (Campath)
or ATG, have been recently utilized, considering that they
might provide a satisfactory clinical outcome with lower
toxicity. The eﬀects of AHSCT on the number of relapses
are considerable; they are usually dramatically reduced; this
anti-inﬂammatory activity is corroborated by the eﬀects of
AHSCT on MRI parameters, with the absence of gadolinium
enhancing lesions on MRI inﬂammatory activity in most
cases for a period of at least 1–3 years.
The main problem of AHSCT is the transplant-related
mortality (TRM), which is around 3.3%. The mortality risk
is mainly due to infections which can occur during the
aplastic phase which follows the conditioning regimen and
are related to the intensity of the therapies used [81–85].
9.How toUse Cy:What WeHaveLearnedfrom
PreviousStudiesandOur Experience
Over the last few years, the use of cy in MS has evolved
towards the use of intermittent pulse therapy given monthly
or bimonthly over a 1- to 3-year period administered
intravenously with an adjusted dose to obtain a leucopoenia
target or with a ﬁxed dose (Table 2, regimen (b) and (c)
respectively). In our experience after the ﬁrst dose, (usually
we start with a dose of 800mg/m2) ,ad o s em o d u l a t i o n
is made on the basis of the number of white blood cells
observed at the nadir of leukopenia (after 12–14 days of
administration). Our target is to keep the white blood cells
below 3000 for mmc and lymphocytes below 800 for mmc.
In our opinion, this target is related to a good balance
between eﬀectiveness and safety. Antiemetic drugs and iv
steroids are usually administered and large amount of ﬂuids
are also administered during the same session of therapy. In
treated patients, we further administer iv MESNA (with a
dose equal to 20% of the dose of cy) before the cy booster
and four hours after the administration of the drug. We also
suggest that the patient should drink a lot (at least two litres
of ﬂuids) in the two days following treatment. MESNA is
used therapeutically to reduce the incidence of hemorrhagic
cystitis and hematuria when a patient receives cy. MESNA
assists the neutralization of the urotoxic metabolites derived
from the metabolism of cy by binding them through their
sulfhydryl group and also increases urinary excretion of
cysteine [86].
10. When to Use Cy: What We Have Learned
from PreviousStudies andOur Experience
Collectively, data from studies indicate that patients with
rapidly worsening, treatment refractory, relapsing-remitting
MS, or in an early secondary progressive phase of the
disease might beneﬁt from treatment with intravenous cy.
We think that in selected patients the drug should be
considered when there are reasons that do not allow use
of ﬁngolimod or natalizumab. Little or nothing appears
to be eﬀective in primary progressive forms of MS. In
order to turn oﬀ inﬂammation from the beginning of the
disease, an innovative approach could be (supported by the
knowledge about MS pathogenesis), in selected patients, a
short early treatment of 12–24 months with cy, followed
by an immunomodulator drug. This approach could be, in
our opinion, a reasonable treatment for a young patient,
suﬀering from RR-MS with a short disease duration, who
shows an “active” clinical disease, characterized by several
relapses over a short period of time (for RR-MS patients)
and/or active MRI disease (deﬁned as either new T2 lesions
or T1 gadolinium enhancing lesions). We can further
consider the option to treat as early as possible, immediately
in patients with a clinically isolated syndrome, with a higher
T2 lesion load and gadolinium enhancing lesions. It is
conceivable that the induction with a more potent agent (cy,
mitoxantrone, natalizumab, alemtuzumab, ﬁngolimod, and
cladribine) followed by a less potent drug (interferons, GA)
may “freeze” and stabilize the disease. The relatively short
periodofinductionwithcyallowsustousecumulativedoses
which are largely below the tolerated cumulative dose of 80–
100g/lifetime. Thus, if after 5–10 or more years patients tend
toreprogress,thereexiststheoptiontotreatwithcyagainfor
some time.
11.Toxicity
The toxic eﬀects of cy in the treatment of neoplastic
or immunomediated diseases are well known [87]. The
most frequent serious adverse event is hemorrhagic cystitis
[88, 89]. Cases of bladder cancer have been observed in
patients who have received long-term cy treatment [90]. For
these, reasons long-term oral cy has been avoided in MS.Autoimmune Diseases 9
Table 3: Data obtained from 200 MS patients treated with cy in our
centre over a ten-year period. ∗of the fertile women.
Side eﬀects %
Nausea and vomit 40
Amenorrhea 18∗
Transitory amenorrhea 60∗
Transitory azoospermia 60
Headache 15
Alopecia (reversible) 13
Fatigue 10
Diﬀuse pain 8
Cutaneous rash 6
Gastritis and diarrhoea 6
Bladder toxicity 6
Infection 3
Cancer risk 1
Arrhythmia 1
Dyspnoea 0.5
Gonadal failure occurs in both men and women receiving
alkylating agents such as cy. Most of the available data
concerns the rate of ovarian failure in cancer survivors.
However, in these patients, alkylating agents were used as
part of a multidrug regimen and at diﬀerent doses than for
immunologic diseases. As concerns the use of cy in immune-
mediated disease, in a lupus nephritis trial, after 6-month
courses then every 3 months of treatment for at least two
more years, with a dose of 0.75mg/m2, and then adjusting
the dose based on the nadir, 23 out of 46 women (50%)
developed amenorrhea [91]. In these studies, an age greater
than 30 years and cumulative dose over 300mg/kg were risk
factors for persistent amenorrhea. The rate of amenorrhea in
women with MS (approximately 40%–80% in large series)
appears similar to that reported for rheumatic diseases [92].
Our data (unpublished) from more than 200 patients treated
withthedrug(aloneorincombinationwithinterferon-beta)
showed a rate of irreversible ovarian failure of 18%, while
transient amenorrhea was observed in 60% of fertile woman
(Table 3)[ 93]. A period of three-six months is considered,
in clinical practice, the minimum period necessary to plan
a pregnancy, after treatment with this drug, but, to date,
there are no studies in the literature that can conﬁrm the
safety of this type of behavior in MS patients. However,
three of our female patients with MS, after a mean period
of 18 months from treatment with cy, became pregnant
and have given birth to healthy babies. There are very few
data concerning the frequency of infertility in men with
immune-mediated diseases treated with cy. We evaluated
the eﬀect of cy on seminal ﬂuid in nine MS patients (6
relapsing-remitting and 3 secondary progressive) treated for
one year with the drug, with a median cumulative dosage
of 22.100mg (5.100–40.100). At the end of treatment, the
evaluation of sperm counts showed that 3 (33%) patients
were azoospermic, 2 (22%) were oligospermic, and 4 (44%)
were normospermic (sperm count >20mil/mL). All patients
showed a decrease in spermatozoa motility (<50%) and
teratospermia (atypical form >30%). All oligospermic and
azospermic patients presented higher serum levels of FSH
and LH [94]. After one year of follow-up, we observed a
recovery of the spermatogenesis in 60% of these patients.
An increased incidence of subsequent malignancies has
been reported in non MS patients treated with cy. This
event may occur a few years after cessation of therapy. The
risk appears to increase as a function of total dose (care
must be taken with cumulative lifetime doses exceeding 80–
100g) [95]. De Ridder et al. observed bladder cancer in
ﬁve patients out of 70 (5.7%) treated with the drug and
chronically catheterized. They suggested regular cystoscopy
in these patients to allow early detection of bladder tumors
[96]. Portaccio et al. assessed the safety and tolerability of
cy “pulse” therapy, in 120 MS patients with progressive or
very active MS who received intravenous monthly “pulses”
of the drug for 12 months at the dosage of 700mg/m2
of body surface, then bimonthly for another 12 months.
They evaluated the frequency and the severity of side
eﬀects, most commonly deﬁnitive amenorrhea (33.3% of
fertile women), hypogammaglobulinemia (5.4%), and hem-
orrhagic cystitis (4.5%). Malignancies were diagnosed in
four (3.6%) subjects, three of whom were previously treated
with azathioprine [97]. As described above, Makhani and
coworkers reviewed their multicentre experience with cy
(cumulative dose between 1.60–72.70g) in the treatment
of 17 children with MS. The side eﬀects observed were
vomiting, transient alopecia, osteoporosis, amenorrhea, and
a bladder carcinoma in one patient [71].
In our center, safety is monitored by obtaining blood
and urine analyses every month and urine cytological
examination every3months;bladder echographyto evaluate
an incomplete empting is obtained before and during treat-
ment, ECG, chest radiography, echography of liver, spleen,
kidney, bladder, uterus and lymph nodes, and mammogra-
phyareperformedevery12months.Analysisofseminalﬂuid
is obtained at the beginning and at the end of treatment. We
suggest sperm cryopreservation or ovarian protection before
cy treatment. We routinely administer a cumulative dose of
about 30 g of the drug divided into monthly boosters over a
period of one-two years. This treatment protocol is safe and
well tolerated. It usually takes less than half of the cumulative
recommended dose thus treatment can resume, if needed,
in the course of the disease. Also, mitoxantrone cannot
be administered safely for long periods. It appears that
after 6-7 boosters, 70mg/m2, mitoxantrone could increase
the risk of cardiotoxicity and leukemia [98–105]. The use
of natalizumab has raised some concerns about the risk
of developing progressive multifocal leukoencephalopathy
(PML). This risk is increased after 24–30 administrations
and if patients had been previously treated with immuno-
suppressive agents [106–108]. However, the results observed
from the patients included in the clinical trials and from the
TOUCH prescribing program clearly indicate that the risk
of PML during treatment with natalizumab is much lower
than that of malignancies during treatment with cy (the risk
ranged from 1/100.000 for the ﬁrst year of treatment until10 Autoimmune Diseases
1/1000 after four years of treatment) [109, 110]. Little is
known about the safe cumulative dosage of the new oral
agents such as cladribine and ﬁngolimod. However, safety
proﬁles of both drugs raise several concerns, even if, to date,
there are no indications about long-term toxicity [110–112].
12. Conclusions andFutureInvestigations
Based on the literature and on our experience, we suggest
that cy could be a therapeutic option in MS patients,
especially if they have an active inﬂammatory component.
On the contrary, in later stages of the disease or in patients
with primary progressive MS the eﬀects of the drug are very
poor. Its ineﬀectiveness in later stages of the disease, when
there is less inﬂammation and more degenerative processes,
appears to be true also for other drugs currently used in the
treatment of the disease.
Given that early inﬂammatory events appear to correlate
with later disability, a major question is whether strong anti-
inﬂammatory drugs such as cy or other drugs currently used
to treat the disease will have an impact on later degenerative
changes if given early in the disease to halt inﬂammation.
With a better understanding of the pathogenesis of the
disease, the possibility to identify new biomarkers and the
introduction of pharmacogenomics and genetics in MS it
may be possible to identify responders and nonresponders
and provide them with a tailored therapy. Without this
information, cy is, in our opinion, a possible treatment
option for people with MS.
From the approval of mitoxantrone for worsening forms
of MS the question remains of the place of cy in this patient
group.
Mitoxantrone is considered easier to administer than
cy. However, because of cardiac toxicity and the observed
high frequency of iatrogenic leukemia, it can only be given
for a limited period and cannot be given again if patients
begin to reprogress. Cy can be used as a retreatment drug
given that the cumulative dose limit is higher than that of
mitoxantrone. However, bladder toxicity can strongly limit
further therapy. For this reason, in our opinion, the use of
cy or mitoxantrone depends, on the clinical condition of the
organs suitable to be damaged by each drug (bladder and
heart, respectively) and by the diligent monitoring over time
of the patient’s clinical conditions to identify and promptly
treat any complications rather than on the cumulative dose.
Furthermore, follow-up needs to be extended for many years
following the treatment period to identify unknown long
term side eﬀects and to detect and treat, as soon as possible
any that occur.
Sequential use of these agents has been carried out by
some investigators, but toxicity proﬁles are unknown at this
time.
We conclude that therapy with cy given in pulse therapy
or in some instances as an acute induction regimen has
an ameliorating eﬀect on the disease process. It could be
used in selected MS patient groups, and in “good hands” it
could be used as induction regimen therapy in larger patient
populations.
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